Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ankyra Therapeutics

News headline image
Ankyra Therapeutics Announces New Scientific Advisory Board Members
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics to Present Data at SITC 2026 Supporting Anchored Immunotherapy with Multiple Cancer-Fighting Agonists for Localized Tumor Treatment
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Presentations on Novel IL-12 Anchored Immunotherapy at 2026 ASCO
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Preclinical Presentation of Anchored Immunotherapy Using Monoclonal Antibodies at PEGS Boston 2026
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Clinical Presentations on Novel IL-12 Anchored Immunotherapy at AACR 2026
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Appoints Robert V. Tighe, an accomplished industry veteran, as Chief Scientific Officer
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Appoints Joseph J. Elassal, M.D., MBA, a Veteran Immuno-oncology Expert, as Chief Medical Officer
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Research Collaboration with the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign
From Ankyra Therapeutics
Via Business Wire
News headline image
Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute
From Ankyra Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.